NorthX Biologics has announced the official inauguration of its Innovation Hub at the Matfors facility.
This milestone marks a major step forward in NorthX’s commitment to the field of advanced therapies in Sweden, states NorthX. The Innovation Hub, co-funded by the Swedish Government, is poised to enhance the country’s infrastructure for cutting-edge therapies and accelerate innovation in the biopharmaceutical sector.
This hub stands as a testament to the collaborative efforts of NorthX and the Swedish Government.”
“We are thrilled to unveil the Innovation Hub at our Matfors facility and it represents our dedication to driving innovation and progress in the field of biopharmaceuticals,” says Janet Hoogstraate, CEO of NorthX Biologics AB. “This hub stands as a testament to the collaborative efforts of NorthX and the Swedish Government, as well as our ongoing commitment to providing cutting-edge solutions to our partners and clients for bringing new therapies to patients.”
Read more: NorthX Biologics expands to cell therapy
With a focus on manufacturing of advanced biologics including Vaccine, Cell and Gene therapies, the Innovation Hub is set to become a catalyst for breakthroughs in medical science, hopes NorthX. This facility supplements NorthX’s existing expertise in Plasmid and Protein manufacturing by adding mRNA services, reinforcing the company’s position as a comprehensive solution provider in the biopharmaceutical industry.
Advancing life-changing therapies
The addition of the Matfors Innovation Hub, combined with the recent acquisition of a site in Stockholm, with facilities and expertise for GMP biomanufacturing through mammalian cell culture processes, further solidifies NorthX’s commitment to advancing life-changing therapies.
Photo of Janet Hoogstraate: Jan Landefeldt